Shares of Puma Biotechnology Inc (NASDAQ:PBYI) have received a consensus recommendation of “Hold” from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $63.11.

PBYI has been the topic of several recent analyst reports. Cowen reiterated a “hold” rating and set a $80.00 price objective on shares of Puma Biotechnology in a report on Friday, August 10th. JPMorgan Chase & Co. increased their price objective on shares of Puma Biotechnology from $80.00 to $83.00 and gave the stock a “buy” rating in a report on Friday, August 10th. BidaskClub lowered shares of Puma Biotechnology from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 15th. Goldman Sachs Group initiated coverage on shares of Puma Biotechnology in a report on Monday, September 17th. They set a “sell” rating and a $42.00 price objective on the stock. Finally, Guggenheim initiated coverage on shares of Puma Biotechnology in a report on Monday, September 17th. They set a “buy” rating on the stock.

Shares of PBYI stock traded down $1.57 during trading hours on Monday, hitting $22.12. 14,472 shares of the company were exchanged, compared to its average volume of 883,982. The firm has a market cap of $903.42 million, a P/E ratio of -2.82 and a beta of 0.22. Puma Biotechnology has a 1 year low of $17.60 and a 1 year high of $108.20. The company has a debt-to-equity ratio of 2.64, a current ratio of 3.01 and a quick ratio of 2.96.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.97) by $0.60. The business had revenue of $62.60 million for the quarter, compared to analyst estimates of $57.94 million. Puma Biotechnology had a negative net margin of 73.45% and a negative return on equity of 301.41%. The company’s revenue was up 926.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.36) EPS. Analysts expect that Puma Biotechnology will post -3.19 earnings per share for the current fiscal year.

In related news, insider Charles R. Eyler sold 1,239 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $22.77, for a total value of $28,212.03. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 21.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Resources Management Corp CT ADV purchased a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $101,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $141,000. Royal Bank of Canada raised its stake in shares of Puma Biotechnology by 271.3% during the first quarter. Royal Bank of Canada now owns 4,021 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 2,938 shares during the period. Oppenheimer Asset Management Inc. purchased a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $213,000. Finally, Marshall Wace LLP purchased a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $289,000. Hedge funds and other institutional investors own 91.64% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Further Reading: Growth Stocks

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.